EG 427's DNA Therapy EG110A Maintains 88% Reduction in Neurogenic Bladder Incontinence at 24 Weeks
核心洞察
EG 427's EG110A DNA therapy sustained an 88% reduction in urinary incontinence (搜索) episodes through 24 weeks in patients with neurogenic detrusor overactivity (搜索) following spinal cord injury (搜索).
The Phase 1b/2a study demonstrated good tolerability with no new safety signals, while the second cohort is being dosed at higher levels.
The therapy targets type C sensory neurons (搜索) responsible for bladder muscle overactivity using non-replicating HSV-1 vector (搜索) technology.
EG 427 announced that its investigational DNA therapy EG110A maintained an 88% reduction in urinary incontinence (搜索) episodes at 24 weeks in patients with neurogenic detrusor overactivity (搜索) (NDO) following spinal cord injury (搜索). The sustained efficacy, first observed at 12 weeks, represents a major milestone for the biotechnology company's Phase 1b/2a dose-escalation study.
The open-label study (ClinicalTrials.gov ID: NCT06596291) continues to demonstrate good tolerability across all patients with no new safety signals reported. Enrollment and dosing of the second cohort is currently ongoing, with researchers evaluating EG110A at higher doses despite the remarkable results achieved with the lowest dose tested.
Novel Mechanism Targets Specific Neurons
EG110A employs a non-replicating HSV-1 vector (搜索) designed to selectively silence type C sensory neurons (搜索) responsible for bladder muscle overactivity while preserving other bladder controls. This precision approach allows the therapy to target a very small number of sensory neurons to achieve dramatic clinical improvements.
"What is truly remarkable, is that by targeting a very small number of sensory neurons, we are able to achieve such a dramatic improvement for the patients," said Philippe Chambon, MD, PhD, Chief Executive Officer at EG 427. "These stellar initial clinical results with EG110A to date are only at the beginning of realizing the potential of our novel approach and our goal of safe and precise DNA medicines for patients with chronic diseases."
Addressing Significant Unmet Medical Need
NDO affects 70-84% of patients living with spinal cord injury (搜索), representing an estimated 300,000-400,000 individuals worldwide. The condition causes uncontrolled urinary incontinence (搜索), risk of kidney damage, and urinary tract infections that can lead to death in 5-10% of the spinal cord injury population.
Altogether, NDO affects at least 2 million patients suffering from spinal cord injury (搜索), multiple sclerosis (搜索), Parkinson's disease (搜索), and other neurodegenerative diseases across the seven major markets. The European Association of Urology recently estimated that incontinence caused by NDO and other indications represents a growing economic burden of over €69.1 billion in 2023 in Europe.
Study Design and Patient Population
The Phase 1b/2a study is enrolling adult participants with NDO following spinal cord injury (搜索) who have persistent urinary incontinence (搜索) after standard of care therapy and perform clean intermittent catheterization regularly. The second cohort includes 6 participants receiving a single treatment course consisting of multiple intradetrusor injections of EG110A.
"For patients, this drop in incontinence episodes combined with a long-term effect could dramatically improve quality of life," said Cornelia Haag-Molkenteller, MD, PhD, Chief Medical Officer at EG 427. "We are continuing to follow these patients up to 52 weeks then will ask them to enroll into a long-term observational study."
The study is being conducted at four leading US institutions located in California, Michigan, Pennsylvania and Texas, with support from the Department of Defense through a $3,165,836 award from the Spinal Cord Injury (搜索) Research Program.
HERMES Platform Technology
EG 427's unique HERMES platform delivers pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. The vectors achieve focal transduction in specific regions and selective expression of transgenes in targeted subsets of neurons through sophisticated regulatory elements. The large payload capacity of non-replicating HSV-1 vectors allows for versatile DNA delivery with demonstrated clinical safety and possible repeated dosing.
This represents the first human study of this type of vector targeting sensory neuron-based diseases, with EG110A being developed to address multiple severe bladder diseases, including overactive bladder (搜索), potentially offering major improvements over existing therapies.